Modular Medical Launches FDA-Cleared Pivot Pump Targeting 70% of Injection-Dependent Adults
MODD•Modular Medical gained FDA 510(k) clearance for its Pivot tubeless insulin patch pump in April and began U.S. commercial shipments, marking its transition to revenue stage. The device’s 3 mL reservoir, two-part design and no-recharge operation targets an estimated 70% of insulin-dependent adults still on injections, representing a multi-billion-dollar market.
1. Commercial Launch of Pivot Pump
Modular Medical commenced U.S. commercial shipments of its Pivot tubeless insulin patch pump following FDA 510(k) clearance in April. This milestone transitions the company from development stage to a revenue-generating commercial-stage medical device manufacturer.
2. Product Features and Benefits
Pivot features a 3 mL reservoir, a two-part removable design and requires no battery recharging, enabling continuous wear during showers and sports while ensuring clinical accuracy and connectivity through an intuitive interface.
3. Market Opportunity
The device addresses an estimated 70% of insulin-dependent adults still on multiple daily injections, a group the company calls “almost-pumpers,” representing a multi-billion-dollar opportunity within the diabetes technology market.
4. Expansion Plan
Full commercial rollout will occur in phases, initially targeting select high-volume endocrinology practices, with broader expansion across multiple metropolitan markets expected by late 2026 as part of a disciplined adoption strategy.
